Abstract: The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.
Type:
Grant
Filed:
March 22, 2011
Date of Patent:
October 22, 2013
Assignee:
Guangzhou Kingmed Center for Clinical Laboratory
Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
October 15, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
Abstract: This invention provides molecularly imprinted polymers (MIPs) for the detection of analytes, methods for forming the MIPs and detecting the analyte using the MIPs. The MIP comprises templated sites which are formed using a mimic of the analyte such that a reporter compound can be selectively attached at the templated sites, thus providing a site selectively tagged and templated MIP.
Type:
Grant
Filed:
December 8, 2004
Date of Patent:
October 15, 2013
Assignee:
The Research Foundation of State University of New York
Abstract: Methods to detect, characterize, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by immunoaffinity bead separation, chromatography, and mass spectrometry are disclosed; Ab-(L-D)p??I wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8.
Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.
Type:
Grant
Filed:
May 2, 2007
Date of Patent:
September 17, 2013
Assignee:
Applied Biosystems, LLC
Inventors:
David W. Ruff, Mark E. Shannon, Kenneth J. Livak, Karl J. Guegler, Kevin M. Hennessy
Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
September 10, 2013
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
Abstract: Disclosed is an agent for inhibiting decrease in measured values in immunoassays, which may reduce the influences by interfering substances in a test sample so as to promote the accuracy of the immunoassays, as well as an immunoassay and a reagent for immunoassays using the same, with which the decrease in the measured values due to the interfering substances is reduced. The agent for inhibiting decrease in measured values in immunoassays, caused by interfering substances, is an ionic surfactant having a molecular weight of 1000 to 100,000, the agent being a polymer in which a hydrophobic cyclic monomer(s) having an ionic functional group(s) is(are) polymerized.
Abstract: An in vivo amperometric sensor is provided for measuring the concentration of an analyte in a body fluid. The sensor comprises a counter electrode and a working electrode, and the working electrode comprises a sensing layer which is generally water permeable and arranged on a support member adjacent to a contact pad. The sensing layer comprises an immobilized enzyme capable of acting catalytically in the presence of the analyte to cause an electrical signal. The sensing layer has an upper surface facing the body fluid and a lower surface facing away from the body fluid, and the immobilized enzyme is distributed within the sensing layer in such a way that the enzyme concentration in the middle between the upper and lower surfaces is at least as high as on the upper surface of the sensing layer.
Type:
Grant
Filed:
December 19, 2008
Date of Patent:
September 3, 2013
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Arnulf Staib, Reinhold Mischler, Martin Hajnsek, Harvey Buck, Walter Jernigan
Abstract: The invention concerns methods of quantification of an analyte, A, in a test sample by means of a single immunochromatographic device, such as a lateral flow device (LFD).
Abstract: The systems of the invention include test cells with a first sorbent material defining a first flow path for a solution, a second sorbent material defining a second flow path distinct from the first flow path for a sample, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc. located at the junction of the first and second sorbent materials. The first and second sorbent strips touch each other at the test site location.
Abstract: The invention provides a method of determining the amount of an analyte having an oxidation potential, for a one electron oxidation process, of about +0.10 to about +1.20 volts at pH 7, relative to the normal hydrogen electrode at 298K, said method comprising measuring the emission intensity or emission lifetime, at two or more wavelengths, from a sample comprising said analyte and two or more different macrocyclic lanthanide (III) complexes, wherein each of said macrocyclic lanthanide (III) complexes comprises a different lanthanide ion but the same macrocyclic ligand, and using a ratio of emission intensities or emission lifetimes measured at two different wavelengths to calculate the amount of analyte in said sample.
Type:
Grant
Filed:
July 11, 2007
Date of Patent:
August 6, 2013
Assignee:
University of Durham
Inventors:
David Parker, Robert Anthony Poole, Filip Kielar
Abstract: A chemiluminescent enzyme immunoassay method for quantifying antigen or antibody using 1,1?-oxalyldiimidazole (ODI) derivative or 1,1?-oxalyldisodium benzoate (ODB) derivative chemiluminescence (CL) detection was developed. Also, various enzymes were quantified using ODI derivative or DOB derivative CL detection. Fluorescent compound formed from a substrate (non-fluorescent compound) through the enzyme assay methods emitted CL when the fluorescent compound received energy from high-energy intermediate formed in ODI derivative or ODB derivative CL reaction.
Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
July 9, 2013
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Thomas Grogan, Fabien Gaire, Mary Padilla, Christopher Bieniarz
Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.
Type:
Grant
Filed:
October 20, 2009
Date of Patent:
July 9, 2013
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health
Inventors:
Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.
Type:
Grant
Filed:
July 30, 2009
Date of Patent:
July 9, 2013
Assignee:
IDEXX Laboratories, Inc.
Inventors:
Yerramilli V. S. N. Murthy, Mahalakshmi Padmanabhan, Michael Atkinson, Kwok Kam Yeung
Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
Type:
Grant
Filed:
November 29, 2011
Date of Patent:
May 28, 2013
Assignee:
Saladax Biomedical Inc.
Inventors:
Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
Abstract: The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.
Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
Type:
Grant
Filed:
November 23, 2011
Date of Patent:
May 14, 2013
Assignee:
Saladax Biomedical Inc.
Inventors:
Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
Abstract: Methods and immunoassays for diagnosing a bite or sting of a venomous organism in a patient having symptoms consistent with such a bite or sting are provided. A sample of venom is collected from the area of the suspected bite or sting using a swab and then contacted with an antibody that specifically binds to an antigenic site on venom present in the sample. Binding is then detected. The invention is illustrated by examples showing diagnosis of brown recluse spider bite, distinguishing it from other diagnoses with which it is often confused. This extremely sensitive test can detect venom antigens down to about 20 picograms even after the sample has been shipped and stored for periods of up to three weeks during the summer.
Type:
Grant
Filed:
April 8, 2010
Date of Patent:
April 23, 2013
Assignees:
SpiderTech, a Division of Stoecker & Associates, a Subsidiary of The Dermatology Center, LLC., The Regents of the University of Michigan, Office of Technology Transfer, The Curators of the University of Missouri, University Hall, The United States of America as Represented by the Secretary of the Air Force, Directorate of Intellectual Property Law
Inventors:
William V. Stoecker, Hernan F. Gomez, Jonathan A. Green, David L. McGlasson